TY - JOUR
T1 - SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia
AU - Elalamy, Ismail
AU - Gerotziafas, Grigoris
AU - Alamowitch, Sonia
AU - Laroche, Jean-Pierre
AU - van Dreden, Patrick
AU - Ageno, Walter
AU - Beyer-Westendorf, Jan
AU - Cohen, Alexander T.
AU - Jimenez, David
AU - Brenner, Benjamin
AU - Middeldorp, Saskia
AU - Cacoub, Patrice
N1 - Publisher Copyright: © 2021 Georg Thieme Verlag. All rights reserved.
PY - 2021/8/1
Y1 - 2021/8/1
N2 - Historically, the vaccination strategies developed in the second half of the 20th century have facilitated the eradication of infectious diseases. From the onset of COVID-19 pandemic to the end of April 2021, more than 150 million cases and 3 million deaths were documented worldwide with disruption of the economic and social activity, and with devastating material, physical, and psychological consequences. Reports of unusual and severe thrombotic events, including cerebral and splanchnic venous thrombosis and other autoimmune adverse reactions, such as immune thrombocytopenia or thrombotic microangiopathies in connection with some of the SARS-CoV-2 vaccines, have caused a great deal of concern within the population and the medical community. This report is intended to provide practical answers following an overview of our knowledge on these thrombotic events that are extremely rare but have serious consequences. Vaccine hesitancy threatens to reverse the progress made in controlling vaccine-preventable diseases. These adverse events must be put into perspective with an objective analysis of the facts and the issues of the vaccination strategy during this SARS-CoV-2 pandemic. Health care professionals remain the most pertinent advisors and influencers regarding vaccination decisions; they have to be supported to provide reliable and credible information on vaccines. We need to inform, reassure, and support our patients when the prescription is made. Facing these challenges and observations, a panel of experts express their insights and propose a tracking algorithm for vaccinated patients based on a 10-point guideline for decision-making on what to do and not to do.
AB - Historically, the vaccination strategies developed in the second half of the 20th century have facilitated the eradication of infectious diseases. From the onset of COVID-19 pandemic to the end of April 2021, more than 150 million cases and 3 million deaths were documented worldwide with disruption of the economic and social activity, and with devastating material, physical, and psychological consequences. Reports of unusual and severe thrombotic events, including cerebral and splanchnic venous thrombosis and other autoimmune adverse reactions, such as immune thrombocytopenia or thrombotic microangiopathies in connection with some of the SARS-CoV-2 vaccines, have caused a great deal of concern within the population and the medical community. This report is intended to provide practical answers following an overview of our knowledge on these thrombotic events that are extremely rare but have serious consequences. Vaccine hesitancy threatens to reverse the progress made in controlling vaccine-preventable diseases. These adverse events must be put into perspective with an objective analysis of the facts and the issues of the vaccination strategy during this SARS-CoV-2 pandemic. Health care professionals remain the most pertinent advisors and influencers regarding vaccination decisions; they have to be supported to provide reliable and credible information on vaccines. We need to inform, reassure, and support our patients when the prescription is made. Facing these challenges and observations, a panel of experts express their insights and propose a tracking algorithm for vaccinated patients based on a 10-point guideline for decision-making on what to do and not to do.
KW - SARS-CoV-2
KW - VITT
KW - thrombosis
KW - vaccination
UR - http://www.scopus.com/inward/record.url?scp=85108974853&partnerID=8YFLogxK
U2 - https://doi.org/10.1055/a-1499-0119
DO - https://doi.org/10.1055/a-1499-0119
M3 - Article
C2 - 33946120
SN - 0340-6245
VL - 121
SP - 982
EP - 991
JO - Thrombosis and haemostasis
JF - Thrombosis and haemostasis
IS - 8
ER -